Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "Jubilant-Pharmova"

46 News Found

USFDA inspection update on Jubilant HollisterStier’s Montreal facility
Drug Approval | September 30, 2024

USFDA inspection update on Jubilant HollisterStier’s Montreal facility

HSGP is engaged closely with the USFDA and is committed to address the OAI observations through planned remediation measures


USFDA determines inspection classification of VAI for the contract manufacturing facility at Spokane, Washington
Drug Approval | September 11, 2024

USFDA determines inspection classification of VAI for the contract manufacturing facility at Spokane, Washington

Jubilant HollisterStier is a subsidiary of Jubilant Pharma Holding


Jubilant receives additional CAD 23.8 million loan facility for CMO Montreal facility
News | March 17, 2023

Jubilant receives additional CAD 23.8 million loan facility for CMO Montreal facility

This loan is in addition to earlier announced CAD 25 million loan committed by the Province of Quebec


Jubilant’s Radiopharma business receives NDA approval for Technetium Mertiatide Injection
Drug Approval | February 02, 2023

Jubilant’s Radiopharma business receives NDA approval for Technetium Mertiatide Injection

The Tc 99m Mertiatide Injection is used in the diagnosis of congenital and acquired renal abnormalities


Dr. Jaidev Rajpal appointed MD & CEO of Jubilant Generics
People | September 15, 2022

Dr. Jaidev Rajpal appointed MD & CEO of Jubilant Generics

He has over two decades of rich experience in management consulting, advising and transforming leading generic pharmaceutical companies in India and global markets


Jubilant receives EIR from USFDA for its radiopharmaceuticals manufacturing facility Montreal Canada
News | August 27, 2022

Jubilant receives EIR from USFDA for its radiopharmaceuticals manufacturing facility Montreal Canada

With the receipt of the EIR, the inspection stands successfully closed.


USFDA removes Jubilant Generics' Olanzapine, Spironolactone and Valsartan from the excepted products list
Drug Approval | July 14, 2022

USFDA removes Jubilant Generics' Olanzapine, Spironolactone and Valsartan from the excepted products list

Post this currently only Risperidone orally disintegrating tablets are allowed for import into the US from the Roorkee facility.


Jubilant HollisterStier announces CAD 100 mn for Montreal facility
News | July 01, 2022

Jubilant HollisterStier announces CAD 100 mn for Montreal facility

The Government of Quebec, through its agent Investissement Quebec, is granting a loan of CAD 25 million


Jubilant HollisterStier enters into agreement of $149.6 mn with US Govt to expand critical vaccine manufacturing capacity
News | June 01, 2022

Jubilant HollisterStier enters into agreement of $149.6 mn with US Govt to expand critical vaccine manufacturing capacity

This agreement is in addition to the $92 million filling line expansion announced in November 2021


Fitch revises outlook on Jubilant Pharma to negative; affirms at 'BB'
News | February 19, 2022

Fitch revises outlook on Jubilant Pharma to negative; affirms at 'BB'

Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).